预防性过敏原疫苗接种:当前和未来的观点。

Patrick G Holt
{"title":"预防性过敏原疫苗接种:当前和未来的观点。","authors":"Patrick G Holt","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Allergen specific immunotherapy has traditionally been viewed as a treatment for established atopic disease. The disease target of choice has principally been allergic rhinitis, and in contrast there has been widespread reluctance in sectors of the clinical community to extend this approach to treatment of atopic asthma. However as understanding of the underlying pathogenic mechanisms which drive asthma aetiology and pathogenesis increases, the rationales for considering immunotherapy in this treatment context are expanding, particularly in relation to primary and secondary prevention of asthma in childhood. This brief review highlights recent development relating to this issue.</p>","PeriodicalId":88824,"journal":{"name":"Arbeiten aus dem Paul-Ehrlich-Institut (Bundesinstitut fur Impfstoffe und biomedizinische Arzneimittel) Langen/Hessen","volume":"96 ","pages":"281-7; discussion 288"},"PeriodicalIF":0.0000,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prophylactic allergen vaccination: current and future perspectives.\",\"authors\":\"Patrick G Holt\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Allergen specific immunotherapy has traditionally been viewed as a treatment for established atopic disease. The disease target of choice has principally been allergic rhinitis, and in contrast there has been widespread reluctance in sectors of the clinical community to extend this approach to treatment of atopic asthma. However as understanding of the underlying pathogenic mechanisms which drive asthma aetiology and pathogenesis increases, the rationales for considering immunotherapy in this treatment context are expanding, particularly in relation to primary and secondary prevention of asthma in childhood. This brief review highlights recent development relating to this issue.</p>\",\"PeriodicalId\":88824,\"journal\":{\"name\":\"Arbeiten aus dem Paul-Ehrlich-Institut (Bundesinstitut fur Impfstoffe und biomedizinische Arzneimittel) Langen/Hessen\",\"volume\":\"96 \",\"pages\":\"281-7; discussion 288\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2009-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Arbeiten aus dem Paul-Ehrlich-Institut (Bundesinstitut fur Impfstoffe und biomedizinische Arzneimittel) Langen/Hessen\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Arbeiten aus dem Paul-Ehrlich-Institut (Bundesinstitut fur Impfstoffe und biomedizinische Arzneimittel) Langen/Hessen","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

过敏原特异性免疫疗法传统上被视为治疗已建立的特应性疾病。选择的疾病目标主要是变应性鼻炎,相反,临床社区的部门普遍不愿意将这种方法扩展到治疗特应性哮喘。然而,随着对驱动哮喘病因和发病机制的潜在致病机制的了解的增加,在这种治疗背景下考虑免疫治疗的理由正在扩大,特别是与儿童哮喘的一级和二级预防有关。这篇简短的综述强调了与这一问题有关的最新发展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Prophylactic allergen vaccination: current and future perspectives.

Allergen specific immunotherapy has traditionally been viewed as a treatment for established atopic disease. The disease target of choice has principally been allergic rhinitis, and in contrast there has been widespread reluctance in sectors of the clinical community to extend this approach to treatment of atopic asthma. However as understanding of the underlying pathogenic mechanisms which drive asthma aetiology and pathogenesis increases, the rationales for considering immunotherapy in this treatment context are expanding, particularly in relation to primary and secondary prevention of asthma in childhood. This brief review highlights recent development relating to this issue.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
History of specific immunotherapy. Legal status and regulation of allergenic products in the United States. Regulation of allergen products in Europe (including NPPs). Current status and regulation of allergen products in Mexico. Regulation of allergen products in Canada: an overview of the current and the proposed regulatory frameworks (draft guidance).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1